Seeking Alpha

Amarin (AMRN) up 4.1% premarket after posting a per-share GAAP loss of $0.18 (a $0.26 loss...

Amarin (AMRN) up 4.1% premarket after posting a per-share GAAP loss of $0.18 (a $0.26 loss excluding compensation and derivative-value issues), roughly in line with analyst expectations of a $0.22-$0.25 loss. The late-stage biopharma noted an FDA approval for a use of its Vascepa capsules in treating hypertriglyceridemia, and the development of eight new patents to go alone with 30 other applications pending.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)